Stay updated with breaking news from Oncoextra Test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target […]
ARK Investment Management LLC lowered its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 37.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,155,098 shares of the medical research company’s stock after selling 4,224,089 shares during the period. […]
Frontier Capital Management Co. LLC lessened its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 13.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 747,966 shares of the medical research company’s stock after selling […]
Sandler Capital Management purchased a new stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 67,181 shares of the medical research company’s stock, valued at approximately $4,556,000. A number of other […]
Rhumbline Advisers grew its position in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 1.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 199,394 shares of the medical research company’s stock after purchasing an additional 2,575 shares during the period. Rhumbline Advisers owned approximately 0.11% […]